Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
measles, mumps and rubella vaccine
- Development stage
- Preclinical
- Lead developer
- Sinovac (Dalian) Vaccine Technology
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
This is a trivalent live attenuated vaccine candidate being developed by Sinovac (Dalian) Vaccine Technology Co., Ltd. for the prevention of measles, mumps, and rubella. The vaccine consists of combined live attenuated strains of the measles virus, mumps virus, and rubella virus, designed to stimulate a protective immune response against all three viral pathogens simultaneously. Sinovac (Dalian) is a member enterprise of the Jingang Group (Dalian Kingport Group Co., Ltd.) and was established as a joint venture with Sinovac Holdings (Hong Kong) Co., Ltd. The vaccine is currently in the preclinical stage of development.
- Other names
- MMR vaccinemeasles-mumps-rubella live attenuated vaccineLive attenuated MMR vaccine
Beyond the preview
Go deeper on measles, mumps and rubella vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on measles, mumps and rubella vaccine.